These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8666002)

  • 1. The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA: Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers.
    Peck RW; Wiggs R; Posner J
    Eur J Clin Pharmacol; 1995; 49(3):243-9. PubMed ID: 8666002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic properties of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyl transferase, and serum cholesterol levels in healthy volunteers.
    Uchida T; Usui T; Watanabe T; Higuchi S; Nakata M; Maezawa K; Kikawa Y; Tsunoo M; Nakaya N; Goto Y
    Eur J Clin Pharmacol; 1997; 51(5):399-406. PubMed ID: 9049582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans.
    Harris WS; Dujovne CA; von Bergmann K; Neal J; Akester J; Windsor SL; Greene D; Look Z
    Clin Pharmacol Ther; 1990 Aug; 48(2):189-94. PubMed ID: 2199133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
    Trivedi BK; Purchase TS; Holmes A; Augelli-Szafran CE; Essenburg AD; Hamelehle KL; Stanfield RL; Bousley RF; Krause BR
    J Med Chem; 1994 May; 37(11):1652-9. PubMed ID: 8201599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats.
    Uchida T; Aoyama K; Watanabe T; Higuchi S
    Atherosclerosis; 1998 Mar; 137(1):97-106. PubMed ID: 9568741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the acylcoenzyme A cholesterol acyltransferase inhibitor 447C88 in plasma using gas chromatography-mass spectrometry and liquid chromatography atmospheric pressure chemical ionisation tandem mass spectrometry.
    Fraser IJ; Clare RA; Pleasance S
    J Chromatogr B Biomed Appl; 1995 Jan; 663(2):275-87. PubMed ID: 7735475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters.
    Sugiyama Y; Ishikawa E; Odaka H; Miki N; Tawada H; Ikeda H
    Atherosclerosis; 1995 Feb; 113(1):71-8. PubMed ID: 7755657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the acyl coenzyme A:cholesterol acyl transferase inhibitor CP-105,191 in dogs--the effect of food and sesame oil on systemic exposure following oral dosing.
    Inskeep PB; Davis KM; Reed AE
    J Pharm Sci; 1995 Feb; 84(2):131-3. PubMed ID: 7738788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
    Krause BR; Black A; Bousley R; Essenburg A; Cornicelli J; Holmes A; Homan R; Kieft K; Sekerke C; Shaw-Hes MK
    J Pharmacol Exp Ther; 1993 Nov; 267(2):734-43. PubMed ID: 8246149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability.
    Bello AA; Bright C; Burton BJ; Bush RC; Casey JH; Dron DI; Facchini V; Joannou PP; Parrott DP; Riddell D; Roberts SA; Williams RJ
    Biochem Pharmacol; 1996 Feb; 51(4):413-21. PubMed ID: 8619885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.
    O'Brien PM; Sliskovic DR; Picard JA; Lee HT; Purchase CF; Roth BD; White AD; Anderson M; Mueller SB; Bocan T; Bousley R; Hamelehle KL; Homan R; Lee P; Krause BR; Reindel JF; Stanfield RL; Turluck D
    J Med Chem; 1996 Jun; 39(12):2354-66. PubMed ID: 8691430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol.
    Riddell D; Bright CP; Burton BJ; Bush RC; Harris NV; Hele D; Moore UM; Naik K; Parrott DP; Smith C; Williams RJ
    Biochem Pharmacol; 1996 Oct; 52(8):1177-86. PubMed ID: 8937424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel acyl-CoA:cholesterol acyltransferase inhibitors. Synthesis and biological activity of 3-quinolylurea derivatives.
    Tawada H; Harcourt M; Kawamura N; Kajino M; Ishikawa E; Sugiyama Y; Ikeda H; Meguro K
    J Med Chem; 1994 Jun; 37(13):2079-84. PubMed ID: 8027989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of a direct effect on hepatic acyl CoA: cholesterol acyl transferase (ACAT) activity by an orally administered enzyme inhibitor in the hamster.
    Burrier RE; Deren S; McGregor DG; Hoos LM; Smith AA; Davis HR
    Biochem Pharmacol; 1994 Apr; 47(9):1545-51. PubMed ID: 8185666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and metabolism of a novel diurea inhibitor of acyl CoA: cholesterol acyltransferase (YM17E) in the rat and dog.
    Uchida T; Nakamura E; Usui T; Imasaki H; Kawakami R; Watanabe T; Higuchi S
    Xenobiotica; 1994 Dec; 24(12):1223-36. PubMed ID: 7771109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters.
    Nakamura S; Kamiya S; Shirahase H; Kanda M; Yoshimi A; Tarumi T; Kurahashi K
    Arzneimittelforschung; 2004; 54(2):102-8. PubMed ID: 15038459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-[2-[N'-pentyl-(6,6-dimethyl-2,4-heptadiynyl)amino]ethyl]- (2-methyl-1-naphthylthio)acetamide (FY-087). A new acyl coenzyme a:cholesterol acyltransferase (ACAT) inhibitor of diet-induced atherosclerosis formation in mice.
    Nagata Y; Yonemoto M; Iwasawa Y; Shimizu-Nagumo A; Hattori H; Sawazaki Y; Kamei T
    Biochem Pharmacol; 1995 Mar; 49(5):643-51. PubMed ID: 7887979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired mobilisation of cholesterol from stored cholesteryl esters in human (THP-1) macrophages.
    Graham A; Angell AD; Jepson CA; Yeaman SJ; Hassall DG
    Atherosclerosis; 1996 Feb; 120(1-2):135-45. PubMed ID: 8645354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
    Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
    Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.